Approximately one in 30 individuals across the world suffers from bipolar disorder (BD). With this prevalence, the pathophysiology of BD represents one of the most important unsolved challenges in neuroscience. Although there appears to be a strong hereditary component to the disorder, genome-wide association studies have failed to identify any obvious underlying developmental or signalling pathways. In this issue, Gaspar et al. (2014) report two significant developments in this area. The first is the report of alterations in the cAMP-CREB signalling pathway in BD, and the second is the possibility of a biomarker and assay specific for the condition.
